144 related articles for article (PubMed ID: 18669475)
1. Another STEPP in the right direction.
Bonetti M; Cole BF; Gelber RD
J Clin Oncol; 2008 Aug; 26(22):3813-4; author reply 3814-5. PubMed ID: 18669475
[No Abstract] [Full Text] [Related]
2. Trend toward noninferiority trials may mean more difficult interpretation of trial results.
Tuma RS
J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926
[No Abstract] [Full Text] [Related]
3. Progression-free survival remains debatable endpoint in cancer trials.
Tuma R
J Natl Cancer Inst; 2009 Nov; 101(21):1439-41. PubMed ID: 19828873
[No Abstract] [Full Text] [Related]
4. Causal inference for definitive clinical end points in a randomized clinical trial with intervening nonrandomized treatments.
Korn EL; Freidlin B
J Clin Oncol; 2010 Aug; 28(24):3800-2. PubMed ID: 20660828
[No Abstract] [Full Text] [Related]
5. A discrete-continuous mixture quantile function estimator with a practical application to phase II cancer clinical trials.
Hutson AD
Stat Med; 2008 May; 27(12):2094-109. PubMed ID: 18038447
[TBL] [Abstract][Full Text] [Related]
6. Statistical inference for cancer trials with treatment switching.
Shao J; Chang M; Chow SC
Stat Med; 2005 Jun; 24(12):1783-90. PubMed ID: 15900586
[TBL] [Abstract][Full Text] [Related]
7. Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?
Saad ED; Buyse M
J Clin Oncol; 2012 May; 30(15):1750-4. PubMed ID: 22393092
[No Abstract] [Full Text] [Related]
8. Cost effectiveness of sunitinib.
Trippoli S; Messori A
J Clin Oncol; 2008 Dec; 26(35):5829; author reply 5829-30. PubMed ID: 19001342
[No Abstract] [Full Text] [Related]
9. The hazards of endpoints.
Berry DA
J Natl Cancer Inst; 2010 Sep; 102(18):1376-7. PubMed ID: 20826734
[No Abstract] [Full Text] [Related]
10. About an adaptively weighted Kaplan-Meier estimate.
Plante JF
Lifetime Data Anal; 2009 Sep; 15(3):295-315. PubMed ID: 19533346
[TBL] [Abstract][Full Text] [Related]
11. Special issue of statistical genetics and genomics in clinical trials: guest editor's note.
Wu R; Lin M
J Biopharm Stat; 2010 Mar; 20(2):191-2. PubMed ID: 20309753
[No Abstract] [Full Text] [Related]
12. The type I error and power of non-parametric logrank and Wilcoxon tests with adjustment for covariates--a simulation study.
Jiang H; Symanowski J; Paul S; Qu Y; Zagar A; Hong S
Stat Med; 2008 Dec; 27(28):5850-60. PubMed ID: 18759373
[TBL] [Abstract][Full Text] [Related]
13. [Development for and clinical trials of molecular targeting drugs].
Takashima A; Fukuda H; Shibata T
Gan To Kagaku Ryoho; 2010 May; 37(5):822-7. PubMed ID: 20524257
[No Abstract] [Full Text] [Related]
14. Re: Visualizing length of survival in time-to-event studies: a complement to Kaplan-Meier plots.
Lama N; Gallo C
J Natl Cancer Inst; 2008 Aug; 100(16):1188; author reply 1188-9. PubMed ID: 18695133
[No Abstract] [Full Text] [Related]
15. Research outcomes and recommendations for the assessment of progression in cancer clinical trials.
Bushnell W; Stone A
J Biopharm Stat; 2013; 23(5):949-50. PubMed ID: 23957508
[No Abstract] [Full Text] [Related]
16. ["Statistically significant"--an overestimation of data value?].
Abel U
Med Klin (Munich); 1999 Apr; 94 Suppl 2():21-2. PubMed ID: 10740397
[No Abstract] [Full Text] [Related]
17. Outcome reporting bias in clinical trials.
Esposito E; Cipriani A; Barbui C
Epidemiol Psichiatr Soc; 2009; 18(1):17-8. PubMed ID: 19378694
[No Abstract] [Full Text] [Related]
18. SOP 14: Population pharmacokinetic analysis.
Onkologie; 2003 Oct; 26 Suppl 6():60-6. PubMed ID: 23570191
[No Abstract] [Full Text] [Related]
19. Updated methods for reporting clinical trials.
Hait WN
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6753-4. PubMed ID: 16203758
[No Abstract] [Full Text] [Related]
20. Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints.
Tuma RS
J Natl Cancer Inst; 2006 Sep; 98(18):1272-4. PubMed ID: 16985244
[No Abstract] [Full Text] [Related]
[Next] [New Search]
